Randomization
Eligible patients were randomized (1:1:1:1:1) via interactive response technology to one of five groups: BI 425809 2 mg, 5 mg, 10 mg, and 25 mg or placebo once daily (QD) in a 12-week double-blind treatment period (Fig. 